Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults

INTRODUCTION: In DUET, etravirine (ETR) 200 mg bid had durable efficacy and a favourable safety profile versus placebo, both arms with an optimised background regimen (BR) including darunavir/ritonavir (DRV/r). TMC125IFD3002 (VIOLIN; NCT01422330) investigated ETR plus ARVs other than DRV/r. MATERIAL...

Descripción completa

Detalles Bibliográficos
Autores principales: Arathoon, Eduardo, Bhorat, Asad, Silaghi, Rodica, Crauwels, Herta, Lavreys, Ludo, Tambuyzer, Lotke, Vanveggel, Simon, Opsomer, Magda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P251
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225395/
https://www.ncbi.nlm.nih.gov/pubmed/25397527
http://dx.doi.org/10.7448/IAS.17.4.19783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225395/
https://www.ncbi.nlm.nih.gov/pubmed/25397527
http://dx.doi.org/10.7448/IAS.17.4.19783

Ejemplares similares